News
DGNOF
0.308
-2.04%
-0.006
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
Barchart · 08/13 13:21
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
Barchart · 07/27 14:20
DIAGNOS to Extend the Exercise Period of Stock Warrants
Barchart · 07/07 11:38
DIAGNOS Announces Shares for Debt Settlement
Barchart · 06/18 11:00
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
Barchart · 06/05 09:00
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
Barchart · 04/01 10:50
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
Barchart · 02/04 08:30
DIAGNOS Announces the Engagement of IBN
Barchart · 01/15 14:30
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
Barchart · 10/22/2025 14:00
DIAGNOS Announces Voting Results of Meeting of Shareholders
Barchart · 09/25/2025 14:30
Weekly Report: what happened at DGNOF last week (0908-0912)?
Weekly Report · 09/15/2025 10:04
More
Webull provides a variety of real-time DGNOF stock news. You can receive the latest news about Diagnos Inc through multiple platforms. This information may help you make smarter investment decisions.
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.